Education
About Us
Working with TipRanks
Follow Us
Scpharmaceuticals (SCPH)
:SCPH
SCPH Stock Chart & Stats
$5.67
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range― - ―
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cost EfficiencyThe autoinjector could reduce costs associated with Furoscix by 70-75%, indicating potential for increased efficiency.
Market AcceptanceThe rapid adoption of Furoscix in chronic kidney disease among nephrologists suggests a strong market acceptance.
Revenue GrowthRevenue of $16.0M exceeded expectations, up 99.2% compared to the previous year.
Bears Say
Competitive InterestNo additional bidders are expected, suggesting limited competitive interest in acquiring scPharmaceuticals beyond the current agreement with MannKind.
Profitability LimitationThe company's ability to invest for growth was limited by the company's balance sheet and the need to achieve profitability.
Stock RecommendationAnalyst downgrades scPharmaceuticals shares to Hold from Buy, reflecting a cautious stance on future stock price appreciation.
scPharmaceuticals News
SCPH FAQ
What was Scpharmaceuticals’s price range in the past 12 months?
Currently, no data Available
What is Scpharmaceuticals’s market cap?
Currently, no data Available
When is Scpharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Scpharmaceuticals’s earnings last quarter?
Scpharmaceuticals released its earnings results on Aug 07, 2025. The company reported -$0.34 earnings per share for the quarter, missing the consensus estimate of -$0.298 by -$0.042.
Is Scpharmaceuticals overvalued?
According to Wall Street analysts Scpharmaceuticals’s price is currently Undervalued.
Does Scpharmaceuticals pay dividends?
Scpharmaceuticals does not currently pay dividends.
What is Scpharmaceuticals’s EPS estimate?
Scpharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Scpharmaceuticals have?
Currently, no data Available
What happened to Scpharmaceuticals’s price movement after its last earnings report?
Scpharmaceuticals reported an EPS of -$0.34 in its last earnings report, missing expectations of -$0.298. Following the earnings report the stock price went down -7.585%.
Which hedge fund is a major shareholder of Scpharmaceuticals?
Currently, no hedge funds are holding shares in SCPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Scpharmaceuticals
scPharmaceuticals Inc. is a biotechnology company focused on the development and commercialization of innovative pharmaceutical products that utilize its proprietary subcutaneous drug delivery technology. The company operates primarily in the healthcare sector, with a core focus on providing treatments for patients with chronic conditions, particularly in the areas of heart failure and other serious illnesses. scPharmaceuticals aims to enhance patient outcomes and improve the convenience of administering medications through its products, which include its lead product candidate, Furoscix, a subcutaneous formulation of furosemide for the treatment of worsening heart failure.
SCPH Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected strong revenue and dosage growth, successful launches, and strategic positioning for future growth through regulatory and market dynamics. However, increased costs and cash flow challenges were noted, along with uncertainties in IDN fulfillment rates.View all SCPH earnings summariesTechnical Analysis
Ownership Overview
― Insiders
1.80% Mutual Funds
― Other Institutional Investors
98.20% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---